Phase 4
Completed N=121
Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®
Source: ClinicalTrials.gov NCT01170884 ↗Enrolled (actual)
121
Serious AEs
0.0%
Results posted
Jan 2012
Primary outcomePrimary: Mean Diurnal Intraocular Pressure (IOP) at Week 12 — 15.4; 19.2 Millimeters of mercury (mm Hg)
Summary
Comparing Safety and Efficacy of Combigan® and Lumigan® with Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated with Xalatan®.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Diurnal Intraocular Pressure (IOP) at Week 12 |
15.4; 19.2 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosed with glaucoma or ocular hypertension.
- Visual Acuity 20/100 or better in both eyes
Exclusion Criteria
- Any active ocular disease
- History of any intraocular surgery or glaucoma laser surgery within 3 months
- Contraindication to pupil dilation
- Use of topical, periorbital, intravitreal, or systemic steroid within 3 months
Data sourced from ClinicalTrials.gov (NCT01170884). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.